<DOC>
	<DOCNO>NCT01125449</DOCNO>
	<brief_summary>The study design determine high dos intravenous ascorbic acid ( vitamin C ) effective manage solid tumor disease . Secondary goal determination palliative effect improvement quality life patient .</brief_summary>
	<brief_title>Study High Dose Intravenous ( IV ) Ascorbic Acid Measurable Solid Tumor Disease</brief_title>
	<detailed_description>Ascorbic acid demonstrate selective cytotoxicity cancer cell vitro , spar normal cell peroxidative effect . This study examine effect , , drug dose patient level sufficient achieve transient serum state 400mg/dl . Safety drug show Phase I study dosed high 1.5gm/kg . Patients treat twice weekly 12 week ( 24-cycles ) evaluate response use RECIST criterion . Patients show stable disease objective response remain study one year absence measurable disease disease progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>18 year old time entry study Disease extent confirm documented CT scan within 45 day entry study normal glucose 6phosphate dehydrogenase current calcium oxalate nephrolithiasis potential reduce urinary flow ability understand inform consent process give inform consent treatment measurable solid tumor neoplastic disease ( use RECIST criterion ) life expectancy great 8weeks agree undergo central line placement ( example : portacatheter , central venous catheter , percutaneously inserted central catheter [ PICC ] line placement ) . Patient regular caregiver must able maintain flush central line direct study physician . ( Study center provide periodic site dress change require ) Failed curative therapy patient ineligible definitive curative therapy Karnofsky performance status least 40 clinically relevant abnormal finding physical examination , clinical chemistry , haematology , urinalysis , vital sign , ECG baseline , opinion investigator , may put subject risk his/her participation study use nicotine product include nicotine patches/gum unstable angina well manage medication history calcium oxalate stone formation pregnancy nurse infant psychiatric disorder history examination would prevent completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ascorbic acid</keyword>
	<keyword>vitamin C</keyword>
	<keyword>antioxidant</keyword>
	<keyword>vitamin</keyword>
</DOC>